Home
Our Company
ProductsPress ReleasesPartneringCareersContact
Featured Post

Kye Pharmaceuticals Secures Exclusive Canadian License, Supply and Commercialization Agreement for a novel proton pump inhibitor (PPI) treatment option for gastroesophageal reflux disease (GERD) in infants, children and adults

May 1, 2025
Read More

July 2, 2024

Kye Pharmaceuticals Announces the Availability of QUILLIVANT® ER Chewable Tablets for the Treatment of Children With ADHD

Read More

October 26, 2023

Kye Pharmaceuticals Partners with Hyloris Pharmaceuticals for the Development and Commercialization of Atomoxetine Oral Solution in Canada

Read More

September 25, 2023

Health Canada approves Quillivant® ER (extended release) oral suspension and chewable tablets for the treatment of ADHD.

Read More

June 1, 2023

Kye Pharmaceuticals Announces Commercial Availability of CORZYNA™ 1000 mg (ranolazine extended-release tablets)

Read More

July 14, 2022

Accrufer® New Drug Submission accepted by Health Canada

Read More

May 24, 2022

KYE Pharmaceuticals Announces John McKendry as President

Read More
Follow us on LinkedIn!
Kye Pharmaceuticals © 2023. All Rights Reserved.  |  Web Design by Aquí.
ContactPrivacy PolicyTerms of Use
Kye Pharmaceuticals © 2023. All Rights Reserved.  Web Design by Aquí.